Ryan D. Lake
2021 - Recro Pharma
In 2021, Ryan D. Lake earned a total compensation of $2.3M as Chief Financial Officer at Recro Pharma, a 7% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $242,887 |
|---|---|
| Option Awards | $744,327 |
| Salary | $425,385 |
| Stock Awards | $867,815 |
| Other | $49,062 |
| Total | $2,329,476 |
Lake received $867.8K in stock awards, accounting for 37% of the total pay in 2021.
Lake also received $242.9K in non-equity incentive plan, $744.3K in option awards, $425.4K in salary and $49.1K in other compensation.
Rankings
In 2021, Ryan D. Lake's compensation ranked 5,440th out of 12,415 executives tracked by ExecPay. In other words, Lake earned more than 56.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 5,440 out of 12,415 | 56th |
Division Manufacturing | 2,294 out of 5,505 | 58th |
Major group Chemicals And Allied Products | 999 out of 2,375 | 58th |
Industry group Drugs | 889 out of 2,096 | 58th |
Industry Pharmaceutical Preparations | 638 out of 1,546 | 59th |
Source: SEC filing on April 1, 2022.
Lake's colleagues
We found one more compensation record of an executive who worked with Ryan D. Lake at Recro Pharma in 2021.
2021
J Enloe
Recro Pharma
Chief Executive Officer
News
Recro Pharma CEO J Enloe's 2022 pay jumps 107% to $2.3M
April 6, 2023
Recro Pharma CFO Ryan Lake's 2021 pay jumps 622% to $2.3M
April 1, 2022
Recro Pharma CFO Ryan Lake's 2020 pay jumps 161% to $2.2M
March 25, 2021
Baudax Bio CEO Gerri Henwood's 2020 pay falls 87% to $603K
March 11, 2021
Recro Pharma CEO Gerri Henwood's 2019 pay jumps 90% to $4.6M
March 27, 2020